Extrait

The main objectives of this study are to evaluate the safety, tolerability, and efficacy of caspofungin therapy, administered as 50 mg/m2 IV once daily (maximum 70 mg/day) following a loading dose of 70 mg/m2 (maximum 70 mg/day) on Day 1, in pediatric patients (3 months through 17 years of age) with invasive aspergillosis (IA) who are refractory to or intolerant of standard therapy or those with invasive or esophageal Candida infections. The specific objectives are: Primary: (1) To report the proportion of pediatric patients treated with caspofungin with one or more drug-related clinical or laboratory adverse experience(s).

Critère d'inclusion

• Candida and Aspergillus infections

Liens

• euctr